BRAIN Biotech AG Asset Resilience Ratio
BRAIN Biotech AG asset resilience ratio. BRAIN Biotech AG (BNN) has an Asset Resilience Ratio of 9.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of BRAIN Biotech AG to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BRAIN Biotech AG (2012–2025)
Asset resilience ratio of BRAIN Biotech AG from 2012 to 2025. This chart shows how BRAIN Biotech AG's Asset Resilience Ratio has changed over time. Read BRAIN Biotech AG (BNN) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BRAIN Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BNN total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.19 Million | 9.33% |
| Short-term Investments | €126.00K | 0.19% |
| Total Liquid Assets | €6.32 Million | 9.52% |
Asset Resilience Insights
- Limited Liquidity: BRAIN Biotech AG maintains only 9.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BRAIN Biotech AG Industry Peers by Asset Resilience Ratio
Compare BRAIN Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hengyi Petrochemical Co Ltd
SHE:000703 |
Specialty Chemicals | 0.06% |
|
Zhejiang Longsheng Group Co Ltd
SHG:600352 |
Specialty Chemicals | 0.80% |
|
Sichuan Tianqi Lithium Industries Inc
SHE:002466 |
Specialty Chemicals | 2.06% |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 1.69% |
|
Jiangsu Pacific Quartz Co Ltd
SHG:603688 |
Specialty Chemicals | 33.15% |
|
Lily Group Co Ltd
SHG:603823 |
Specialty Chemicals | 0.37% |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238 |
Specialty Chemicals | 40.33% |
|
Dalian Bio-Chem Co Ltd
SHG:603360 |
Specialty Chemicals | 1.45% |
BRAIN Biotech AG Asset Resilience Ratio by Year (2012–2025)
BRAIN Biotech AG asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for BRAIN Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 9.52% | €6.32 Million ≈ $7.38 Million |
€66.34 Million ≈ $77.55 Million |
-21.16pp |
| 2024-09-30 | 30.69% | €27.23 Million ≈ $31.83 Million |
€88.74 Million ≈ $103.74 Million |
+23.06pp |
| 2023-09-30 | 7.62% | €5.41 Million ≈ $6.32 Million |
€70.94 Million ≈ $82.93 Million |
-3.67pp |
| 2022-09-30 | 11.29% | €8.80 Million ≈ $10.29 Million |
€77.99 Million ≈ $91.18 Million |
-20.42pp |
| 2021-09-30 | 31.71% | €24.65 Million ≈ $28.82 Million |
€77.74 Million ≈ $90.88 Million |
+5.31pp |
| 2020-09-30 | 26.40% | €19.05 Million ≈ $22.27 Million |
€72.15 Million ≈ $84.35 Million |
+3.38pp |
| 2019-09-30 | 23.02% | €15.22 Million ≈ $17.80 Million |
€66.12 Million ≈ $77.30 Million |
-11.62pp |
| 2018-09-30 | 34.65% | €25.80 Million ≈ $30.16 Million |
€74.46 Million ≈ $87.06 Million |
-22.34pp |
| 2017-09-30 | 56.99% | €39.04 Million ≈ $45.64 Million |
€68.50 Million ≈ $80.09 Million |
+17.71pp |
| 2016-09-30 | 39.28% | €18.66 Million ≈ $21.82 Million |
€47.51 Million ≈ $55.55 Million |
+38.29pp |
| 2015-09-30 | 0.99% | €299.85K ≈ $350.55K |
€30.41 Million ≈ $35.55 Million |
-6.98pp |
| 2013-09-30 | 7.97% | €2.00 Million ≈ $2.34 Million |
€25.10 Million ≈ $29.34 Million |
-13.55pp |
| 2012-09-30 | 21.52% | €4.24 Million ≈ $4.96 Million |
€19.71 Million ≈ $23.04 Million |
-- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more